Links between chronic disease and cancer risk have been emphasized at various levels, including the World Health Organization. In terms of susceptibility to cancer, individuals with systemic lupus (SLE) have been shown to have distinct cancer risk profiles. Compared to the general population, current data indicate a slight increase in cancer in SLE overall. Within these data, the most evident increased risk is of hematologic cancers, specifically non-Hodgkin lymphoma. In contrast, certain cancers, such as breast, endometrial, and ovarian cancers, may have a decreased risk in persons with SLE, according to recent data. Though, in the past 10 years, a lot has been learnt regarding cancer risk in SLE, much remains unknown. Potentially, both SLE activity itself, and some of the drugs used to treat it, might serve as risk factors for certain malignancies;however, potentially some agents could protect against other cancer types, e.g. breast cancer. Though evidence points to a link between SLE and a decreased risk of breast cancer, the etiology behind this association is unknown. This provides further motivation for more research in this complex field. The primary objectives of our application are: 1. To describe breast cancer cases from an large SLE cohort, with respect to demographics and histology. 2. To assess the importance of drug exposures in persons SLE, regarding breast cancer risk. Here we will estimate the effects of selected medication exposures, adjusting for demographics, reproductive history, smoking and other clinical factors (SLE duration and activity). As secondary objectives, we will determine 1 and 5 year survival rates in the SLE patients who developed breast cancer. Our analyses will be based on data obtained from our multi-site international cohort study of over 16,000 SLE patients. Cancer cases have been ascertained via tumor registry linkage. Relevance: By studying a population like women with SLE, who have such a striking decreased risk of breast cancer, we may learn lessons that can be used to better understand interactions between various risk factors for cancer in the general population. Our project acknowledges that cancer etiology is multi-factorial, and will provide a better understanding of how different factor modify and interact in cancer pathogenesis. Our application answers to several high-priority areas in cancer epidemiology research identified by NIH and the National Cancer Institute, including identification of risk/susceptibility factors, and clinical and translational epidemiolog.

Public Health Relevance

Systemic lupus erythematosus (SLE) is a chronic immune system disease that mostly affects women, and which is linked with a decreased risk of breast cancer, compared to the general population. It is possible that either the disease of SLE itself, and/or some of the drugs used to treat SLE, might protect against breast cancer. The objectives of our application are to describe breast cancer cases that occur in SLE patients, and to assess the possible effects of disease activity, drugs, and other factors, on breast cancer risk in SLE.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Small Research Grants (R03)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Filipski, Kelly
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mcgill University Health Center Research Institute
Zip Code
H3 2R9
Bernatsky, S; Ramsey-Goldman, R; Petri, M et al. (2017) Breast cancer in systemic lupus. Lupus 26:311-315
Noble, Philip W; Bernatsky, Sasha; Clarke, Ann E et al. (2016) DNA-damaging autoantibodies and cancer: the lupus butterfly theory. Nat Rev Rheumatol 12:429-34
Ramsey-Goldman, Rosalind; Brar, Amarpali; Richardson, Carrie et al. (2016) Standardised incidence ratios (SIRs) for cancer after renal transplant in systemic lupus erythematosus (SLE) and non-SLE recipients. Lupus Sci Med 3:e000156
Bernatsky, Sasha; Smargiassi, Audrey; Johnson, Markey et al. (2015) Fine particulate air pollution, nitrogen dioxide, and systemic autoimmune rheumatic disease in Calgary, Alberta. Environ Res 140:474-8
Goobie, Gillian C; Bernatsky, Sasha; Ramsey-Goldman, Rosalind et al. (2015) Malignancies in systemic lupus erythematosus: a 2015 update. Curr Opin Rheumatol 27:454-60
Tessier Cloutier, B; Clarke, A E; Ramsey-Goldman, R et al. (2013) Breast cancer in systemic lupus erythematosus. Oncology 85:117-21
Lu, Mary; Bernatsky, Sasha; Ramsey-Goldman, Rosalind et al. (2013) Non-lymphoma hematological malignancies in systemic lupus erythematosus. Oncology 85:235-40
Kiss, Emese; Kovacs, Laszlo; Szodoray, Peter (2010) Malignancies in systemic lupus erythematosus. Autoimmun Rev 9:195-9
Bernatsky, Sasha; Ramsey-Goldman, Rosalind; Clarke, Ann E (2009) Malignancy in systemic lupus erythematosus: what have we learned? Best Pract Res Clin Rheumatol 23:539-47